白蛋白结合型紫杉醇联合腹腔灌注顺铂治疗老年晚期卵巢癌的临床观察  

作　　者：于韦韦[1] 王翠华[1] 佟倩[1] 

机构地区：[1]大连市第三人民医院肿瘤一病房,辽宁116033

出　　处：《当代医学》2014年第35期73-74,共2页Contemporary Medicine

摘　　要：目的探讨白蛋白结合型紫杉醇联合腹腔灌注顺铂在治疗老年晚期卵巢癌的疗效及安全性。方法回顾性分析晚期卵巢癌患者21例。采用白蛋白结合型紫杉醇80mg/m^2静滴,d1、8。DDP40 mg腹腔热灌注,d 2、9,每3周重复1次,2个周期评价疗效。结果CR 1例,PR 13例,SD 2例,PD5例,总有效率(RR)66.7%,疾病控制率(DCR)71.2%,中位无进展生存期(PFS)1 0.1个月。常见不良反应为Ⅰ~Ⅱ骨髓抑制、Ⅰ~Ⅱ胃肠道反应及1外周神经毒性。结论白蛋白结合型紫杉醇联合腹腔灌注化疗在治疗老年晚期卵巢癌疗效较好,老年患者耐受性好,值得临床进一步推广。Objective To evaluate the therapeutic efifcacy and the safety of albumin-bound paclitaxel combined with intraperitoneal injection in elderly patients with advanced ovarian cancer. Methods Retrospectively analysis 21 patients with advanced ovarian cancer who were received from February 2012 to February 2014. They were given albumin-bound paclitaxel （80 mg/m^2, ivgtt, d 1、8）,and DDP （40 mg, d 2、9）with intraperitoneal peffusion. Every 3 weeks was a course of treatment. The efifcacy and side effects were evaluated after 2 courses of treatment. Results Numbers of complete response,partial response,stable disease progression disease of patients were 1, 13, 2 and 5 respectively. Of 21 patients, the RR was 66.7%, the DCR was 71.2%, the median PFS was 10.1 months. The most frequent treatment-ralated adverse events were myelosuppression, gastrointestinal reaction, and peripheral neuropathy. Conclusion Albumin-bound paclitaxel combined with intraperitoneal injection in advanced ovarian cancer is effective with minimal adverse reactions and can be tolerated by elderly patients, so it is worthy of clinical promotion.

关 键 词：白蛋白结合型紫杉醇 顺铂 晚期卵巢癌 腹腔灌注化疗 

分 类 号：R737.31[医药卫生—肿瘤]